JAK inhibitors

JAK inhibitors

Drug monograph · NCLEX study reference
Trade names	Xeljanz, Rinvoq, Olumiant
Therapeutic class	Targeted synthetic DMARD
Pharmacologic class	Janus kinase (JAK) inhibitors
Onset / peak / duration	Effect over weeks; oral once or twice daily.
Half-life / level	Short to moderate; no routine level.
Routes	PO (oral)
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	Supportive care.
Pregnancy / lactation	Use only if clearly needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

JAK inhibitors (brand names Xeljanz, Rinvoq, Olumiant) — Targeted synthetic DMARD; Janus kinase (JAK) inhibitors.

Identification

• Therapeutic class: Targeted synthetic DMARD.
• Pharmacologic class: Janus kinase (JAK) inhibitors.

Pharmacology

• Mechanism of action: Inhibit JAK signaling to reduce inflammatory cytokine activity; oral (not biologic).
• Onset / peak / duration: Effect over weeks; oral once or twice daily.
• Half-life / therapeutic level: Short to moderate; no routine level.

Clinical use

• Indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and others.
• Usual dose, route, frequency: PO once or twice daily.
• Maximum dose / adjustments: Reduce in renal and hepatic impairment; screen for tuberculosis and hepatitis.

Safety

• Contraindications: Active serious infection; caution with thrombosis and cardiovascular risk.
• Black box warning: Serious infections, increased mortality, malignancy (including lymphoma), major adverse cardiovascular events, and thrombosis.
• Interactions: Strong CYP3A4 inhibitors, other immunosuppressants, live vaccines (avoid).
• Pregnancy / lactation: Use only if clearly needed.
• High-alert: No.

Adverse effects

• Common side effects: Upper respiratory infections, headache, nausea, elevated lipids.
• Serious effects to report: Serious infections, blood clots (leg or lung), cardiovascular events, malignancy.
• Antidote / reversal: Supportive care.

Nursing process

• Assessment before administration: Tuberculosis and hepatitis screening, lipid panel, CBC, clot and cardiovascular risk.
• Interventions during therapy: Hold for serious infection; monitor labs; avoid live vaccines.
• Monitor: CBC, lipids, LFTs, infection, signs of thrombosis.
• Evaluation / expected outcome: Reduced disease activity.

Patient teaching

• Patient teaching: Report infections, chest pain, or leg swelling; avoid live vaccines.
• Notify provider if: Fever or infection, chest pain or shortness of breath, leg swelling.
• Administration tips: Oral daily; screen before starting.